<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04742348</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00009051</org_study_id>
    <nct_id>NCT04742348</nct_id>
  </id_info>
  <brief_title>Research on Translational Outcomes of Alcohol (Project RETRO)</brief_title>
  <official_title>Research on Translational Outcomes of Alcohol (Project RETRO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of the current study is to assess the effect of a single dose of&#xD;
      carbidopa-levodopa on ad libitum alcohol consumption and alcohol craving in young adults with&#xD;
      a history of binge drinking.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a small (N = 42) 2-arm, double-blind, randomized controlled pilot study to assess the&#xD;
      effect of a single dose of immediate release carbidopa-levodopa (50mg/500mg) to acutely&#xD;
      reduce alcohol consumption and craving in college students with a history of heavy episodic&#xD;
      drinking. Participants will be between 21-24 years old from 2- and 4- year colleges in the&#xD;
      Seattle Metropolitan area. Interested students will contact the study line and provide verbal&#xD;
      consent to be sent a link to an online screening survey. Eligible participants will be&#xD;
      scheduled to come in for the ad libitum alcohol administration. Participants will receive&#xD;
      either the carbidopa-levodopa or a placebo and complete the alcohol administration protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alcohol Consumption</measure>
    <time_frame>1 hour</time_frame>
    <description>Number of alcoholic drinks consumed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alcohol Craving</measure>
    <time_frame>30 minutes in to alcohol administration</time_frame>
    <description>Amount of alcohol craving as assessed by the Alcohol Urge Questionnaire by Bohn, Krahn &amp; Staehler (1995)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alcohol craving</measure>
    <time_frame>At the end of alcohol administration. Alcohol administration is 1 hour.</time_frame>
    <description>Amount of alcohol craving as assessed by the Alcohol Urge Questionnaire by Bohn, Krahn &amp; Staehler (1995)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Alcohol Drinking</condition>
  <arm_group>
    <arm_group_label>Control, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Similar looking tablet(s) to active drug will be administered in a single dose to those who are randomly assigned to this group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Drug, Carbidopa + Levodopa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of immediate release carbidopa-levodopa (50mg/500mg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbidopa Levodopa</intervention_name>
    <description>Participants who are randomized to active drug group will receive 1 dose of immediate release carbidopa-levodopa (50mg/500mg) .</description>
    <arm_group_label>Active Drug, Carbidopa + Levodopa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants who are randomized to placebo group will be provided with similar looking tablet(s) as the active drug.</description>
    <arm_group_label>Control, Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Enrolled in 2- or 4-year college program&#xD;
&#xD;
          -  Currently living in the Seattle Metropolitan area&#xD;
&#xD;
          -  Have at least two or more episodes of heavy episodic drinking (4/5 or more drinks in a&#xD;
             2 hours for women/men) in the past 30 days.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclusion criteria include:&#xD;
&#xD;
          -  past-month severe alcohol or other substance use disorders,&#xD;
&#xD;
          -  mood or anxiety disorder&#xD;
&#xD;
          -  suicidal ideation&#xD;
&#xD;
          -  risk of psychotic disorders&#xD;
&#xD;
          -  excessive alcohol use reaching a Blood Alcohol Level greater than .30%&#xD;
&#xD;
          -  history of serious medical conditions, regular use of prescription psychotropic or&#xD;
             pain medication&#xD;
&#xD;
          -  history of negative reactions to alcohol&#xD;
&#xD;
          -  history of treatment for alcohol use disorder&#xD;
&#xD;
          -  pregnancy or nursing.&#xD;
&#xD;
          -  use of non-selective monoamine oxidase inhibitors in the past 2 weeks.&#xD;
&#xD;
          -  narrow-angle glaucoma&#xD;
&#xD;
          -  undiagnosed skin lesions,&#xD;
&#xD;
          -  have a history of melanoma, cardiac issues or peptic ulcer.&#xD;
&#xD;
          -  Currently taking or prescribed any form of levodopa or D2 agonists, D2 antagonists,&#xD;
             isoniazid, methylphenidate, bupropion, Viagra, or phosphodiesterase inhibitors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brittney Hultgren, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Canning</last_name>
    <phone>206-543-6974</phone>
    <email>jrcannin@uw.edu</email>
  </overall_contact>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 9, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2021</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Brittney Hultgren</investigator_full_name>
    <investigator_title>Acting Assistant Professor Department of Psychiatry and Behavioral Sciences</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

